CR:DOI:e5a504f06e86a949236f0995923d2dbc
From IDWiki
{{#scite:
|reference=drayson2019le
|type=journal-article
|title=Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
|author=Mark T Drayson;Stella Bowcock;Tim Planche;Gulnaz Iqbal;Guy Pratt;Kwee Yong;Jill Wood;Kerry Raynes;Helen Higgins;Bryony Dawkins;David Meads;Claire T Hulme;Irene Monahan;Kamaraj Karunanithi;Helen Dignum;Edward Belsham;Jeff Neilson;Beth Harrison;Anand Lokare;Gavin Campbell;Michael Hamblin;Peter Hawkey;Anna C Whittaker;Eric Low;Janet A Dunn|+sep=;
|journal=The Lancet Oncology
|publisher=Elsevier BV
|year=2019
|volume=20
|issue=12
|pages=1760-1772
|doi=10.1016/s1470-2045(19)30506-6
|issn=1470-2045
|retrieved-from=https://dx.doi.org/
|retrieved-on=2024-09-27
}}
